A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2016
At a glance
- Drugs Cobimetinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 21 Jan 2016 According to ClinicalTrials.gov record,primary end points has been revised.
- 21 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.